OH-AMERICHEM
5.4.2024 04:34:26 CEST | Business Wire | Press release
Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal. EcoVadis is a globally recognized assessment platform that rates businesses' sustainability in various categories. This result places Americhem amongst the top 15% of companies assessed by EcoVadis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404483358/en/
Americhem has earned the EcoVadis Silver Medal for Sustainability (Graphic: Business Wire)
The EcoVadis rating also covers a broad range of non-financial management systems including Environmental, Labor and Human Rights, Ethics, and Sustainable Procurement impacts. Americhem’s CEO, John Richard states, “I want to express my deepest gratitude to every employee and partner who has played a role in helping us attain this remarkable achievement. This marks only the beginning for Americhem to set new standards, keep delivering excellence, and pushing boundaries within our sustainability goals.”
Americhem has made major steps forward in sustainability efforts over the past year. Centering a plan around Process, Product, and People has focused Americhem to hone efforts into the areas that matter most and can have the greatest impact. In terms of Process, Americhem’s Denmark plant pioneered a Cold Pounding technology that reduces energy usage by up to 85% and cuts emissions by up to 20% in comparison to conventional compounding processes. The facility is also powered solely by wind and solar energy from RECs Certified suppliers. In the United States, Americhem is recognized as an Operation Clean Sweep® member, with many sites having pledged to achieve zero resin pellet, flake, and powder loss to help keep materials out of the marine environment. In addition, Americhem's plants embrace recycling-compliant packaging, collaborating with customers for the reuse of packaging materials including plastic drums.
On the product front, Americhem has developed numerous technologies that empower customers to attain their sustainability objectives. Solution Dyeing, a technology used in the carpet and textile production processes, eliminates the need for excessive water usage and reduces carbon emissions significantly compared to traditional dyeing processes. Americhem’s flagship additive masterbatch nBalance® allows Post-Consumer Recycled (PCR) materials, which have a yellow tint, to be restored to PET PCR that visually mimics virgin PET.
Americhem recognizes the significance of creating a sustainable environment for both its employees and the communities it serves. The company has also been taking significant steps in its dedication to People Sustainability. By encompassing measures to enhance employee well-being through safety and health initiatives, fostering higher employee engagement through senior management efforts, contributing to charitable causes, and actively participating in volunteer activities, Americhem has noticed an overall increase in employee satisfaction.
Looking ahead, Americhem is committed to making bigger strides in its sustainability journey. In addition to continuous improvement in manufacturing processes, the company plans to further enhance its product portfolio to include sustainability features in most products, develop new product lines for physical and chemical recycling applications, and establish ongoing Life Cycle Assessment (LCA) and Carbon Footprint Analysis on all products.
Americhem would like to thank EcoVadis for their commitment to ensuring that companies remain conscious in their efforts toward a more sustainable future. To learn more about Americhem, please visit: www.americhem.com
About Americhem
Americhem is an innovative, technology-driven leader in the global polymer industry. Its foundation is built around delivering Performance, Solutions and Trust through close collaboration with customers. All of the company's products are backed by complete technical support that ensures quality, reliability, and value. Americhem operates 10 manufacturing plants and maintains sales offices throughout the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404483358/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
